173 related articles for article (PubMed ID: 9538139)
1. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
2. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
[TBL] [Abstract][Full Text] [Related]
3. Bioflavonoids, type II [H-3]estradiol binding sites and prostatic cancer cell proliferation.
Markaverich B; Alejandro M
Int J Oncol; 1997 Dec; 11(6):1311-9. PubMed ID: 21528340
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with a nuclear type-ii site agonist and 5-Fluorouracil - inhibition of mammary-tumor growth.
Markaverich B; Schauweker T; Gregory R; Varma R; Varma M; Kittrell F; Medina D
Int J Oncol; 1993 Mar; 2(3):385-92. PubMed ID: 21573566
[TBL] [Abstract][Full Text] [Related]
5. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.
Markaverich BM; Vijjeswarapu M
Int J Biomed Sci; 2012 Dec; 8(4):219-32. PubMed ID: 23675277
[TBL] [Abstract][Full Text] [Related]
7. Nuclear type-ii [h-3] estradiol binding-sites in mcf-7 human breast-cancer cells - binding interactions with 2,6-bis-([3,4-dihydroxyphenyl]-methylene)cyclohexanone esters and inhibition of cell-proliferation.
Markaverich B; Varma M; Densmore C; Tiller A; Schauweker T; Gregory R
Int J Oncol; 1994 Jun; 4(6):1291-300. PubMed ID: 21567051
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
9. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo .
Kubota T; Hisatake J; Hisatake Y; Said JW; Chen SS; Holden S; Taguchi H; Koeffler HP
Prostate; 2000 Feb; 42(3):163-71. PubMed ID: 10639186
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo inhibition of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats.
Ho SM; Viccione T; Yu M
J Steroid Biochem Mol Biol; 1993 Oct; 46(4):489-95. PubMed ID: 8217879
[TBL] [Abstract][Full Text] [Related]
11. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
12. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
Markaverich BM; Gregory RR
Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
[TBL] [Abstract][Full Text] [Related]
13. Effects of androgen and estradiol administration on the weight of the ventral prostate, seminal vesicles, and testes of immature rats.
Jackson AC; Tenniswood M; Bird CE; Clark AF
Invest Urol; 1977 Mar; 14(5):351-55. PubMed ID: 844996
[TBL] [Abstract][Full Text] [Related]
14. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
15. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
[TBL] [Abstract][Full Text] [Related]
16. Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of noble rats.
Ho SM; Yu M
Cancer Res; 1993 Feb; 53(3):528-32. PubMed ID: 7678774
[TBL] [Abstract][Full Text] [Related]
17. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
[TBL] [Abstract][Full Text] [Related]
18. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
19. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol.
Maybruck WM; Markaverich BM
Steroids; 1997 Mar; 62(3):321-30. PubMed ID: 9071742
[TBL] [Abstract][Full Text] [Related]
20. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
Yang F; Song L; Wang H; Wang J; Xu Z; Xing N
PLoS One; 2015; 10(5):e0128277. PubMed ID: 26011145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]